New hope for tough cancers: first human trial of Oxygen-Targeting drug begins
NCT ID NCT04954599
Summary
This early-stage trial is testing a new drug called CP-506 in adults with advanced solid tumors that have spread or are hard to treat. The study aims to find a safe dose and see if the drug, given alone or with other standard cancer treatments, can shrink tumors. It will enroll up to 126 patients to first check for safety and then look for early signs that the treatment is working.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Academisch Ziekenhuis Maastricht (Leading Centre)
RECRUITINGMaastricht, Limburg, 6229HX, Netherlands
Contact
-
Erasmus MC
RECRUITINGRotterdam, Netherlands
Contact
-
Institut Jules Bordet
NOT_YET_RECRUITINGBrussels, Belgium
Contact
-
Institut Vall d'Hebron
NOT_YET_RECRUITINGBarcelona, 08035, Spain
Contact Phone: •••-•••-••••
-
UZ Gent
NOT_YET_RECRUITINGGhent, 9000, Belgium
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.